A Phase 1 Study of LCAR-C182A Cells in the Treatment of Advanced Gastric Cancer and Pancreatic Ductal Adenocarcinoma
A Phase 1, Open-Label Study Evaluating the Safety, Tolerability and Efficacy of LCAR-C182A, an Anti-Claudin18.2 CAR-T Cell Therapy in Patients With Advanced Gastric Cancer and Pancreatic Ductal Adenocarcinoma
Sponsor: First Affiliated Hospital Xi'an Jiaotong University
Terminated
the Preliminary data, progress of this study and the adjustment of the pipeline and strategy .
Other terminated trials from First Affiliated Hospital Xi'an Jiaotong University
See all terminations from First Affiliated Hospital Xi'an Jiaotong University
Listed as NCT03890198, this EARLY_PHASE1 trial focuses on Gastric Cancer and Pancreatic Ductal Adenocarcinoma and remains terminated or withdrawn. Sponsored by First Affiliated Hospital Xi'an Jiaotong University, it has been updated 8 times since 2019, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Terminated EARLY_PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Terminated EARLY_PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated EARLY_PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated EARLY_PHASE1
-
Aug 2020 — Jan 2021 [monthly]
Terminated EARLY_PHASE1
Status: Recruiting → Terminated
▶ Show 3 earlier versions
-
Dec 2019 — Aug 2020 [monthly]
Recruiting EARLY_PHASE1
-
Jun 2019 — Dec 2019 [monthly]
Recruiting EARLY_PHASE1
Status: Not Yet Recruiting → Recruiting
-
Apr 2019 — Jun 2019 [monthly]
Not Yet Recruiting EARLY_PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- First Affiliated Hospital Xi'an Jiaotong University
- Nanjing Legend Biotech Co.
For direct contact, visit the study record on ClinicalTrials.gov .